The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study DOI Creative Commons
Jenny Nyqvist, Mostafa Helou,

Khalil Helou

et al.

Breast Cancer Research and Treatment, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 12, 2025

To evaluate the prognostic significance of changes in pre- and post-neoadjuvant chemotherapy (NACT) Ki67 patients with primary invasive triple-negative breast cancer (TNBC). Population-based registry data were retrieved for diagnosed TNBC between 2007 2021 (n = 9262). Multivariable Cox regression analysis was performed disease-specific survival (DSS) overall (OS) adjusted age residual disease nodes (RDBN). Of 1777 receiving NACT, 54 achieved pathologic complete response (pCR) 755 had disease. Most overweight stage II (78%), grade 3 tumors (53%), RDBN score (42%). Compared to baseline, tumor size (30 vs. 15 mm; P < 0.0001) levels (63% 48%; 2.2e - 16) generally decreased after NACT. Although only 5% samples increased size, often remained unchanged (75%) or (0.9%) treatment, respectively. However, 34% discontinued treatment. Patients showing no Ki67% more unfavorable OS (P DSS 0.00032), significantly lower 5-year probabilities (OS: 66%; DSS: 78%) than those 87%; 89%). All reaching pCR alive 5 years diagnosis. an independent predictor multivariable analyses. treated neoadjuvant chemotherapy, resulting adverse clinical outcomes. These findings highlight need individualized treatment regimens dynamic monitoring high post-NACT.

Language: Английский

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes DOI Creative Commons
Oreste ­Gentilini, Edoardo Botteri,

Claudia Sangalli

et al.

JAMA Oncology, Journal Year: 2023, Volume and Issue: 9(11), P. 1557 - 1557

Published: Sept. 21, 2023

Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging patients with early breast cancer (BC), but its necessity can be questioned since surgery examination nodes not performed curative intent.

Language: Английский

Citations

207
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality DOI Creative Commons
Amanda Kerr, David Dodwell,

Paul McGale

et al.

Cancer Treatment Reviews, Journal Year: 2022, Volume and Issue: 105, P. 102375 - 102375

Published: March 4, 2022

Adjuvant and neoadjuvant breast cancer treatments can reduce mortality but may increase from other causes. Information regarding treatment benefits risks is scattered widely through the literature. To inform clinical practice we collated reviewed highest quality evidence.Guidelines were searched to identify adjuvant or options recommended in early invasive cancer. For each option, systematic literature searches identified highest-ranking evidence. radiotherapy risks, for dose-response relationships modern organ doses also undertaken.Treatment USA elsewhere included chemotherapy (anthracycline, taxane, platinum, capecitabine), anti-human epidermal growth factor 2 therapy (trastuzumab, pertuzumab, trastuzumab emtansine, neratinib), endocrine (tamoxifen, aromatase inhibitor, ovarian ablation/suppression) bisphosphonates. Radiotherapy after conserving surgery (whole breast, partial tumour bed boost, regional nodes) mastectomy (chest wall, nodes). Treatment supported by randomised evidence, including > 10,000 women eight comparisons, 1,000-10,000 fifteen < 1,000 one. Most comparisons reduced recurrence 10-25%, with no non-breast-cancer death. Anthracycline increased overall mortality. risk was heart disease leukaemia. Radiation-risks mainly disease, lung oesophageal cancer, increasing heart, oesophagus radiation respectively. Taxanes leukaemia risk.These decisions individuals recommendations groups of women.

Language: Английский

Citations

201
Breast cancer: an up‐to‐date review and future perspectives DOI Creative Commons
Ruoxi Hong, Binghe Xu

Cancer Communications, Journal Year: 2022, Volume and Issue: 42(10), P. 913 - 936

Published: Sept. 8, 2022

Breast cancer is the most common worldwide. The occurrence of breast associated with many risk factors, including genetic and hereditary predisposition. cancers are highly heterogeneous. Treatment strategies for vary by molecular features, activation human epidermal growth factor receptor 2 (HER2), hormonal receptors (estrogen [ER] progesterone [PR]), gene mutations (e.g., 1/2 [BRCA1/2] phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [PIK3CA]) markers immune microenvironment tumor-infiltrating lymphocyte [TIL] programmed death-ligand 1 [PD-L1]). Early-stage considered curable, which local-regional therapies (surgery radiotherapy) cornerstone, systemic therapy given before or after surgery when necessary. Preoperative neoadjuvant therapy, targeted drugs checkpoint inhibitors, has become standard care early-stage HER2-positive triple-negative cancer, followed risk-adapted post-surgical strategies. For ER-positive early endocrine 5-10 years essential. Advanced distant metastases currently incurable. Systemic in this setting include agents, such as CDK4/6 inhibitors phosphoinositide (PI3K) hormone receptor-positive disease, anti-HER2 poly(ADP-ribose) polymerase BRCA1/2 mutation carriers immunotherapy part disease. Innovation technologies precision medicine may guide individualized treatment escalation de-escalation future. In review, we summarized latest scientific information discussed future perspectives on cancer.

Language: Английский

Citations

196
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) DOI
Michael Gnant, Amylou C. Dueck,

Sophie Frantal

et al.

Journal of Clinical Oncology, Journal Year: 2021, Volume and Issue: 40(3), P. 282 - 293

Published: Dec. 7, 2021

Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.

Language: Английский

Citations

177
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 DOI Creative Commons
Giuseppe Curigliano, Harold J. Burstein, Michael Gnant

et al.

Annals of Oncology, Journal Year: 2023, Volume and Issue: 34(11), P. 970 - 986

Published: Sept. 6, 2023

The 18th St Gallen International Breast Cancer Conference held in March 2023, Vienna, Austria, assessed significant new findings for local and systemic therapies early breast cancer with a focus on the evaluation of multimodal treatment options. emergence more effective, innovative agents both preoperative (primary or neoadjuvant) post-operative (adjuvant) settings has underscored pivotal role multidisciplinary approach decision making, particularly when selecting therapy an individual patient. importance discussions regarding clinical benefits interventions was explicitly emphasized by consensus panel as integral part developing optimal plan 'right' degree intensity duration. panelists focused controversies surrounding management common ductal/no special type lobular histology, which account vast majority tumors. expert opinion based interpretations available data, well current practices their professional environments, personal socioeconomic factors affecting patients, cognizant varying reimbursement accessibility constraints around world. strongly advocated patient participation well-designed studies whenever feasible. With these considerations mind, Consensus aims to offer guidance clinicians appropriate treatments early-stage assist balancing realistic trade-offs between benefit toxicity, enabling patients make well-informed choices through shared decision-making process.

Language: Английский

Citations

108
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial DOI
Sara M. Tolaney, Paolo Tarantino, Noah Graham

et al.

The Lancet Oncology, Journal Year: 2023, Volume and Issue: 24(3), P. 273 - 285

Published: Feb. 27, 2023

Language: Английский

Citations

104
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials DOI Creative Commons
Jeremy Braybrooke, Rosie Bradley, Richard Gray

et al.

The Lancet, Journal Year: 2023, Volume and Issue: 401(10384), P. 1277 - 1292

Published: April 1, 2023

Language: Английский

Citations

102
The pyroptotic role of Caspase-3/GSDME signalling pathway among various cancer: A Review DOI
Asif Ahmad Bhat, Riya Thapa, Obaid Afzal

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 242, P. 124832 - 124832

Published: May 15, 2023

Language: Английский

Citations

100
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment DOI Creative Commons
Federica Miglietta, Gaia Griguolo, Michele Bottosso

et al.

npj Breast Cancer, Journal Year: 2022, Volume and Issue: 8(1)

Published: May 20, 2022

Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described high instability expression from primary cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline biopsy and residual disease (RD) patients undergoing neoadjuvant treatment did not include the category. The aim this study is track evolution BC RD after treatment. Patients with available tumor tissue matched samples (in case no pCR) were included. cases sub-classified HER2-0 or (IHC 1+ 2+ ISH negative). Four-hundred forty-six Primary phenotype was: HR-positive/HER2-negative 23.5%, triple-negative (TN) 35%, HER2-positive 41.5%. 55.6% cohort significantly enriched vs. TN subgroup (68.6% 46.8%, p = 0.001 χ2 test). In all, 35.3% non-pCR (n 291) had on RD. overall rate was 26.4%, mostly driven by converting either (14.8%) (8.9%) phenotype. Among RD, 32.0% 57.1% an estimated risk relapse according proliferative burden CPS-EG score, respectively. conclusion, showed may guide personalized adjuvant for high-risk context clinical trials novel anti-HER2 antibody-drug conjugates.

Language: Английский

Citations

79
PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway DOI Creative Commons
Rui Zhang,

Mengxue Dong,

Juchuanli Tu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: March 1, 2023

Our previous studies have showed that C-C motif chemokine ligand 20 (CCL20) advanced tumor progression and enhanced the chemoresistance of cancer cells by positively regulating breast stem cell (BCSC) self-renewal. However, it is unclear whether CCL20 affects remodeling microenvironment (TME). Here, we observed polymorphonuclear myeloid-derived suppressor (PMN-MDSCs) were remarkably enriched in TME CCL20-overexpressing orthotopic allograft tumors. Mechanistically, activated differentiation granulocyte-monocyte progenitors (GMPs) via its receptor 6 (CCR6) leading to PMN-MDSC expansion. PMN-MDSCs from tumors (CCL20-modulated PMN-MDSCs) secreted amounts C-X-C 2 (CXCL2) increased ALDH+ BCSCs activating CXCR2/NOTCH1/HEY1 signaling pathway. Furthermore, (CXCR2) antagonist SB225002 docetaxel (DTX) effects on growth decreasing CCL20high-expressing These findings elucidated how modulated promote development, indicating a new therapeutic strategy interfering with interaction between cancer, especially cancer.

Language: Английский

Citations

64